Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions. An article by TARA HAELLE PUBLISHED August 03, 2018 The fact that JOHN MACLEOD'S colorectal cancer expresses a RAS gene mutation has limited his treatment options. - PHOTO BY KONNOR J … Continue reading ‘Cracking the Nut’ on RAS Mutations
Blue Ribbon Run
The Blue Ribbon Run raises money for the Julie M. Brown and Christina M. Gianoplus Fund for Colon Cancer Research from Wilmington, NC. Ana Boudreau, who co-sponsored the run, had set up the fund along with a volunteer committee. With their combined efforts they seek to break the silence surrounding colon cancer, secure funds for … Continue reading Blue Ribbon Run
PurpleStride Raleigh-Durham 2018: Running RAScals
UNC's Running RAScals (aka the Der Lab at UNC Lineberger & Friends) participated in this year’s PanCAN #PurpleStride run on Saturday, April 21st. This 5k run raises money to support the Pancreatic Cancer Action Network. The team, organized by Kirsten Bryant, raised $10,839 to support Pancreatic Cancer Research, coming in Fifth in overall fundraising! This was the Der Lab's fifth … Continue reading PurpleStride Raleigh-Durham 2018: Running RAScals
News radio 680 WPTF on Pancreatic Cancer
Rick and Donna Martinez have a morning live interview show featuring conversations with community personalities and leaders about issues that impact you. We are happy to share the March 1, 2018 radio podcast with our own Pancreatic Cancer Experts Channing Der, PhD and Kirsten Bryant, PhD. This interview discusses common perceptions of Pancreatic Cancer; Symptoms … Continue reading News radio 680 WPTF on Pancreatic Cancer
NPR Focuses on One of the Biggest Challenges in Pancreatic Cancer: KRAS
This article was posted on the Pancreatic Cancer Action Network on March 9, 2018 by Allison Rosenweig, PhD. KRAS protein structure, reproduced with permission from NCI, FNLCR About 95 percent of pancreatic cancer cases – and around 30 percent of all human cancers – have a mutation in a gene called RAS. The resulting mutated … Continue reading NPR Focuses on One of the Biggest Challenges in Pancreatic Cancer: KRAS
Merck’s ERK inhibitor shows promise in combo against resistant cancers
by Amirah Al Idrus | Feb 22, 2018 fiercebiotech.com One-fifth of patients in a phase 1 study responded to an investigational ERK inhibitor from Merck, bolstering hopes that this type of drug could be used effectively in combination with other cancer drugs. ERK is a cell signal that is believed to drive the growth of … Continue reading Merck’s ERK inhibitor shows promise in combo against resistant cancers
Der Lab 